RemeGen's new lupus drug debuts in Times Square

Chinese leading biotech innovator, RemeGen made its debut on a billboard-sized screen in New York's famous Times Square on Dec 2 following its breakthrough in clinical trials of a new drug to treat lupus.

The new drug Telitacicept, independently developed by RemeGen, is proved to have strong effect on treating systemic lupus, rheumatoid arthritis and autoimmune diseases.

RemeGen, headquartered in Yantai in East China's Shandong province, was established in 2008 and also has R&D facilities in Beijing and San Francisco.

It is a biopharmaceutical company focusing on the research and development of innovative biological drugs with independent intellectual property rights.

The company has developed a series of new drugs with independent intellectual property rights for autoimmune diseases, malignant tumors and other major human diseases.

Times Square is the busiest area in New York and is known as the "crossroads of the world". Ten million business elites gather there every year, and it is one of the global business core areas and famous landmarks of the Big Apple.